[go: up one dir, main page]

CL2013003324A1 - Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón. - Google Patents

Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.

Info

Publication number
CL2013003324A1
CL2013003324A1 CL2013003324A CL2013003324A CL2013003324A1 CL 2013003324 A1 CL2013003324 A1 CL 2013003324A1 CL 2013003324 A CL2013003324 A CL 2013003324A CL 2013003324 A CL2013003324 A CL 2013003324A CL 2013003324 A1 CL2013003324 A1 CL 2013003324A1
Authority
CL
Chile
Prior art keywords
composition
clusterine
carboplatin
paclitaxel
oligonucleotide
Prior art date
Application number
CL2013003324A
Other languages
English (en)
Inventor
Chen Duksin
Shoshi Tesser
Martin Gleave
Original Assignee
Teva Pharma
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Univ British Columbia filed Critical Teva Pharma
Publication of CL2013003324A1 publication Critical patent/CL2013003324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION QUE COMPRENDE QUIMIOTERAPIA CON PACLITAXEL Y CARBOPLATINO Y UN OLIGONUCLEOTIDO ANTI-CLUSTERINA; USO DE LA COMPOSICIÓN PARA EL TRATAMIENTO DE UN PACIENTE HUMANO QUE PADECE CANCER DE PULMÓN.
CL2013003324A 2011-05-19 2013-11-19 Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón. CL2013003324A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487918P 2011-05-19 2011-05-19
US201161493346P 2011-06-03 2011-06-03

Publications (1)

Publication Number Publication Date
CL2013003324A1 true CL2013003324A1 (es) 2014-08-01

Family

ID=47177396

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003324A CL2013003324A1 (es) 2011-05-19 2013-11-19 Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.

Country Status (17)

Country Link
US (1) US20130017272A1 (es)
EP (1) EP2709673A4 (es)
JP (1) JP2014520081A (es)
KR (1) KR20140034838A (es)
CN (1) CN103958681A (es)
AR (1) AR086514A1 (es)
AU (1) AU2012257487A1 (es)
CA (1) CA2836676A1 (es)
CL (1) CL2013003324A1 (es)
EA (1) EA201391725A1 (es)
IL (1) IL227720A0 (es)
MX (1) MX2013013384A (es)
PE (1) PE20140647A1 (es)
PH (1) PH12013502402A1 (es)
SG (1) SG194931A1 (es)
WO (1) WO2012156817A2 (es)
ZA (1) ZA201309254B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2830195A1 (en) 2011-03-15 2012-09-20 Martin E. Gleave Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
UY34812A (es) * 2012-05-18 2013-12-31 Teva Pharma Método para el tratamiento del cáncer de pulmón de células no pequeñas
CA2903239A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Custirsen treatment with reduced toxicity
US20140275215A1 (en) * 2013-03-14 2014-09-18 Teva Pharmaceutical Industries, Ltd. Anti-clusterin monotherapy for cancer treatment
US20160324439A1 (en) * 2015-05-06 2016-11-10 Taiwan Textile Research Institute Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
RU2017145940A (ru) * 2015-05-29 2019-07-02 Дайнэвокс Текнолоджиз Корпорейшн Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
KR20190115505A (ko) 2018-03-15 2019-10-14 특허법인 해담 기업 맞춤형 후속 개발 아이템 발굴 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2469685C (en) * 2002-01-17 2013-03-12 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CN101076546B (zh) * 2004-09-02 2011-10-26 Isis药物公司 用于低聚物合成的聚合珠

Also Published As

Publication number Publication date
EP2709673A4 (en) 2014-12-17
IL227720A0 (en) 2013-09-30
WO2012156817A3 (en) 2013-02-21
EA201391725A1 (ru) 2014-05-30
JP2014520081A (ja) 2014-08-21
PE20140647A1 (es) 2014-06-05
WO2012156817A9 (en) 2013-01-03
WO2012156817A2 (en) 2012-11-22
PH12013502402A1 (en) 2014-01-13
SG194931A1 (en) 2013-12-30
CN103958681A (zh) 2014-07-30
ZA201309254B (en) 2015-05-27
EP2709673A2 (en) 2014-03-26
AR086514A1 (es) 2013-12-18
KR20140034838A (ko) 2014-03-20
CA2836676A1 (en) 2012-11-22
US20130017272A1 (en) 2013-01-17
MX2013013384A (es) 2014-06-11
AU2012257487A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
MX2015011753A (es) Metodos para tratar cancer de vegija.
EA201400178A1 (ru) Лечение рака молочной железы
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
UY33866A (es) Terapia anticancer
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
MX378273B (es) Compuestos activos hacia bromodominios.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
UY32987A (es) Nuevo uso antitumoral de cabazitaxel
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.